Healthcare provider profile · identity verified

Stanley Teeten, MD

Internal Medicine · BAKERSFIELD, CA · NPI 1609943521

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	652	222
Lisinopril	Lisinopril	318	114
Amlodipine Besylate	Amlodipine Besylate	303	113
Losartan Potassium	Losartan Potassium	279	103
Rosuvastatin Calcium	Rosuvastatin Calcium	243	100
Levothyroxine Sodium	Levothyroxine Sodium	220	74
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	185	56
Pantoprazole Sodium	Pantoprazole Sodium	165	58
Alendronate Sodium	Alendronate Sodium	159	58
Simvastatin	Simvastatin	156	50
Tamsulosin Hcl	Tamsulosin Hcl	156	59
Omeprazole	Omeprazole	155	61
Albuterol Sulfate Hfa	Albuterol Sulfate	153	65
Glipizide	Glipizide	150	57
Metformin Hcl	Metformin Hcl	138	54
Metformin Hcl Er	Metformin Hcl	120	55
Atenolol	Atenolol	110	39
Gabapentin	Gabapentin	98	33
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	98	37
Clopidogrel	Clopidogrel Bisulfate	96	31
Meloxicam	Meloxicam	96	39
Jardiance	Empagliflozin	89	31
Metoprolol Tartrate	Metoprolol Tartrate	87	33
Terazosin Hcl	Terazosin Hcl	87	33
Prednisone	Prednisone	82	77
Azelastine Hcl	Azelastine Hcl	76	24
Tramadol Hcl	Tramadol Hcl	74	21
Ibuprofen	Ibuprofen	73	25
Hydrochlorothiazide	Hydrochlorothiazide	70	26
Ezetimibe	Ezetimibe	67	24
Montelukast Sodium	Montelukast Sodium	66	20
Potassium Chloride	Potassium Chloride	65	30
Wixela Inhub	Fluticasone Propion/Salmeterol	59	23
Spiriva Respimat	Tiotropium Bromide	56	18
Hydralazine Hcl	Hydralazine Hcl	55	20
Finasteride	Finasteride	52	19
Glipizide Er	Glipizide	51	16
Metoprolol Succinate	Metoprolol Succinate	51	23
Verapamil Er	Verapamil Hcl	49	17
Allopurinol	Allopurinol	44	18
Ozempic	Semaglutide	44	suppressed
Trazodone Hcl	Trazodone Hcl	43	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	41	11
Humulin N	Insulin Nph Human Isophane	40	16
Propranolol Hcl	Propranolol Hcl	40	11
Bisoprolol Fumarate	Bisoprolol Fumarate	39	12
Sumatriptan Succinate	Sumatriptan Succinate	37	suppressed
Alvesco	Ciclesonide	36	22
Famotidine	Famotidine	36	18
Pradaxa	Dabigatran Etexilate Mesylate	35	14
Triamcinolone Acetonide	Triamcinolone Acetonide	35	15
Acyclovir	Acyclovir	33	12
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	33	15
Buspirone Hcl	Buspirone Hcl	32	14
Duloxetine Hcl	Duloxetine Hcl	32	13
Doxycycline Monohydrate	Doxycycline Monohydrate	29	22
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	28	14
Carvedilol	Carvedilol	27	suppressed
Cephalexin	Cephalexin	27	25
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	27	27
Colchicine	Colchicine	26	suppressed
Sertraline Hcl	Sertraline Hcl	26	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	26	23
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	25	suppressed
Clobetasol Propionate	Clobetasol Propionate	24	suppressed
Estradiol	Estradiol	24	suppressed
Ciclopirox	Ciclopirox	23	12
Risedronate Sodium	Risedronate Sodium	23	suppressed
Furosemide	Furosemide	22	13
Ondansetron Odt	Ondansetron	22	13
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	21	21
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	19	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Topiramate	Topiramate	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Lorazepam	Lorazepam	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Sucralfate	Sucralfate	16	suppressed
Temazepam	Temazepam	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Pitavastatin Calcium	Pitavastatin Calcium	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Eliquis	Apixaban	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Ibandronate Sodium	Ibandronate Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error